Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

Find Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Near You

Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates. This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle. The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Undergoing diagnostic evaluation for suspected lung cancer

• Spirometry showing obstructive airflow limitation (FEV₁/FVC \< 75 % or FEV₁ \< 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation

Locations
Other Locations
Denmark
Lung Cancer Investigation Unit, Lillebaelt Hospital Vejle
RECRUITING
Vejle
Contact Information
Primary
Ditte Krag-Hansen, MD, PhD student
ditte.krag-hansen@rsyd.dk
+45 7940 5720
Backup
Morten Hornemann Borg, MD, PhD, Chief consultant
morten.hornemann.borg@rsyd.dk
Time Frame
Start Date: 2026-03-06
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 280
Treatments
No_intervention: Usual care
Lung cancer investigation only
Experimental: Tailored COPD consultation
Tailored COPD consultations will include assessment and treatment according to GOLD guidelines, including:~Pharmacological management Smoking cessation support Referral to pulmonary rehabilitation as appropriate Referral for nutritional assessment and optimization when appropriate Referral to cardiovascular evaluation when appropriate Referral to sleep apnea evaluation when appropriate
Sponsors
Collaborators: AstraZeneca, Sygehus Lillebaelt
Leads: Ditte Krag-Hansen

This content was sourced from clinicaltrials.gov